A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Combination therapy with RAS inhibitors shows promise for pancreatic cancer regression and resistance prevention

This research article presents a study on a targeted combination therapy for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest c

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer patients

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds

An experimental pill called daraxonrasib has shown promise in helping patients with advanced pancreatic cancer live longer. The drug blocks

New daily pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients

A new daily pill called daraxonrasib, which targets a gene behind pancreatic cancer, nearly doubled overall survival time for patients with